Study of HS-10504 in people with liver problems
Part of Digestive system clinical trials.
This study looks at how the body handles a new investigational drug (HS-10504) in people with liver problems compared to those with healthy liver function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults with either normal liver function or chronic liver disease (like cirrhosis) that is stable.
- Willing to use effective contraception (both men and women) during the study and for 6 months after.
- For people with liver problems: your liver condition must be stable, and you must be on a steady medication regimen for the last 14 days (or on none).
- For people with normal liver function: you must not have any liver disease and not take certain medications or supplements within 14 days before the study.
- No major surgery within 3 months, no significant blood loss or donation, and no participation in other clinical trials recently.
- Able to avoid alcohol and limit smoking to less than 5 cigarettes per day during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine for people with mild or moderate liver problems to see how the liver affects the drug in the body. It also includes people with normal liver function for comparison.
This trial tests an investigational drug, HS-10542, in healthy adults to see how it is processed by the body and to check for side effects. You must be willing to receive two vaccines before the study starts.
This study looks at how the body handles the study drug HS-10365 in people with liver problems compared to those with healthy livers. It helps find the right dose and safety information for future patients.
This trial tests a new drug called HS-10504 in healthy adults to see how the body processes it. It is an early-phase study that helps determine safe dosing.
This study looks at how a new oral drug (HS-10241) is processed by the body in people with mild to moderate liver disease and in healthy people. It helps find the right dose and safety for future patients with liver problems.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
Hear when a new To Compare the Pharmacokinetic (PK) Differences of HS-10504 Between Participants With Hepatic Impairment and Participants With Normal Hepatic Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.